Why Partner?
Connect with a Community of 60+ Translational & Clinical Pharmacology Experts from Leading ADC Companies
The 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit brings together leading experts driving innovation in ADC development. Focused on pharmacokinetics, clinical pharmacology, and modeling and simulation this intimate, focused forum will explore how these disciplines can optimize dose selection, improve safety and efficacy, and accelerate clinical success.
With 60+ senior decision-makers in PK, pharmacometrics, and clinical pharmacology in attendance, solution providers have a unique opportunity to showcase their expertise, demonstrate the impact of their tools and services, and build collaborations that directly influence the future of ADC development.
What To Expect:
Connect with a focused audience of ADC developers committed to minimizing dose-related risks and staying ahead of evolving regulatory expectations
Highlight your brand as a trusted partner in drug development by showcasing your expertise in modeling strategies that support confident dosing decisions and regulatory success
Demonstrate your ability to integrate quantitative modeling with biological insight, meeting the increasing demand for partners who deliver both scientific rigor and practical solutions
Explore emerging trends in PK/PD and pharmacometrics while cultivating relationships with the next generation of ADC developers advancing into clinical development
Key Services & Solutions:
Our attendees from ADC biopharma are looking for service and solution providers with capabilities in the below areas but are not limited to:
Bridging PK/PD modeling and ADC biology to deliver predictions that mirror real-world behavior and drive confident dosing decisions
Transparent, robust models that support regulatory interactions, optimize clinical outcomes, and de-risk ADC development from the start
In silico modelling and simulation providers to help select the right dose for the right patient with improved timelines
Bioanalytical CROs who will undertake the studies to characterize PK through analytes to understand how drug is behaving post-administration
Preclinical and clinical CROs who incorporate in silico modelling into their solutions, for informed drug development decisions
Attending Companies Include:
Contact Us:
George Shrimpton
Senior Partnerships Director
sponsor@hansonwade.com
US: +1 617 455 4188